Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31297972 | 0.85 | HRH4 (0.45) | GAAALOX5RAB9ACTSLCTSB | |
| SCHEMBL31298102 | 0.81 | GAA (0.44) | GAAALOX5RAB9ANPC1ALDH1A1 | |
| SCHEMBL31298060 | 0.78 | SIGMAR1 (0.58) | GAAALOX5RAB9AALDH1A1TSHR | |
| SCHEMBL10293597 | 0.77 | CHRNB2 (0.60) | GAAALDH1A1ACHEHPGDHSD17B10 | |
| SCHEMBL14304554 | 0.77 | CHRNB2 (0.60) | GAAALDH1A1ACHEHPGDHSD17B10 | |
| SCHEMBL31298053 | 0.76 | KDM1A (0.48) | GAA | |
| SCHEMBL31298011 | 0.75 | L3MBTL3 (0.52) | GAAACHEDRD4 | |
| SCHEMBL31298051 | 0.75 | KMT2A (0.62) | GAAALOX5RAB9ANPC1ALDH1A1 | |
| SCHEMBL6403300 | 0.74 | GAA (0.47) | GAAALOX5RAB9ANPC1CTSL | |
| SCHEMBL31298017 | 0.73 | OPRD1 (0.47) | ALDH1A1ACHEHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2025-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | WNT1, XPOT, CTNNBL1 | GAA 4758/4885ALOX5 4736/4885RAB9A 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.